metastases (liver, lung, bone or brain) at diagnosis. Liver was the most common metastatic site (1183, 50.6%), followed by bone (801,34.3%), lung (701,29.9%) and brain (616,26.4%). Patients with isolated lung metastases (1-, 5-year OS: 63.2%, 43.2%; 1-, 5-year LCSS: 74.0%, 62.9%,) had significantly better outcomes comparing to other patterns of metastases. The outcomes of patients with any brain metastases was most unfavorable (1-, 5-year OS: 20.3%, 2.1%, p<0.001; 1-, 5-year LCSS: 26.8%, 7.7%, p<0.001). Multivariate Cox regression analysis on OS and LCSS revealed that age > 60 years (p<0.001), male gender (p<0.001), poorer differentiation (p<0.001) and brain metastases (p<0.001) were independently poor prognostic factors for stage IV lung NETs patients. Conclusion: The prognostic impact of metastatic site was unambiguous in stage IV patients with lung NETs. Comparing other metastatic patterns, brain metastases was associated with significant worse survival outcomes. Nearly twenty-fold difference in 5-year survival was revealed between isolated lung and brain metastases. For advanced lung NETs patients, brain metastases might be considered as a distinct category of dismal outcomes.
Background: Prophylactic cranial irradiation (PCI) remains a standard of care for small cell lung cancer (SCLC) to improve overall survival (OS) and prevent recurrence in limited (LS) and extensive stage (ES) disease. Intracranial recurrence (IC) after PCI affects 12-33%. Limited published data describe outcomes of salvage reirradiation (ReRT). Our purpose was to review outcomes after IC post-PCI or therapeutic whole brain radiotherapy (WBRT). Method: Consecutive patients with pathologically-confirmed SCLC assessed (01/2013-12/2015) at a tertiary cancer centre (catchment 1.5M) were retrospectively reviewed. Demographics, treatment and outcomes were abstracted and summary statistics calculated. Kaplan-Meier estimates and univariate and multivariate analysis (MVA) via the Cox proportional hazard model were performed. Result: Median age was 66.1yrs, 53% female, and 80% ECOG 0-2 (N ¼372). Median survival (MS) was 24 months (95%CI 18.3-29.7 mos) for 103 LS, and 7 months (95%CI 6.1-7.9 mos) for 269 ES patients. 72/103 LS received PCI (69.9%), 84.7% of whom had radical thoracic radiotherapy (RT). 54/269 ES patients presented with brain metastases (BM); 98/215 of the remaining received PCI, and 72 of those thoracic RT (84.7% 25-30Gy/10). PCI dose was 25Gy/10 in 95.9%. PCI patients had better performance status (PS), and were more likely to receive chemotherapy (CT) and thoracic RT (all p<0.013). 18.8% (32/170) recurred post-PCI (13 LS; 19 ES) at a median of 11.5 mos. 45/54 presenting with BM received WBRT (83.3% 20Gy/5), 14 of whom recurred. MS after PCI was 28 mos vs 12 mos for LS and ES, respectively. For LS patients with IC post-PCI, MS was 20 mos vs 38 mos without IC (p¼0.03). On MVA, interval between brain RT predicted OS after PCI (HR 0.87; p<0.001), while stage (HR 3.56; p¼0.008) and cranial RT dose predicted IC (HR 0.65; p¼0.047). At IC, 56.5% (26/46) had <5 BM, median 1.7cm (range 0.5-5cm), 39.1% had no extracranial disease, 6 were asymptomatic, and 50% had ECOG 0-2. 30/46 had ReRT: 27 WBRT and 3 stereotactic radiosurgery (SRS). In retrospect, 17/46 would have been candidates for salvage SRS: 5 LS post-PCI; 8 ES post-PCI; and 4 ES post-WBRT. Conclusion: This cohort seems to challenge the belief that in-brain progression is always: diffuse; Background: Prophylactic cranial irradiation (PCI) reduces the incidence of brain metastasis (BM) and improves overall survival (OS) in limited-stage Small Cell Lung Cancer (LS-SCLC) patients with complete or partial remission after receiving chemoradiotherapy. However, cranial magnetic resonance imaging (CMRI) before scheduled PCI is not mandatory, and its necessity remains controversial. Therefore, we conducted this study to evaluate LS-SCLC patients' BM rate revealed by CMRI immediately before PCI. Method: 283 consecutive LS-SCLC patients diagnosed at our center between 2014 and 2017 were evaluated, all have negative base-line CMRI. Patients received platinum-based chemotherapy plus concurrent or sequential thoracic radiation. 119 complete or partial responders were identified. All received another CMRI immediately before PCI and constituted the cohort of interest. Logistic regression was employed to assess the relationship between pre-PCI BM risk and the following variables: age, gender, smoking history, lymph node stage or time from treatment initiation to pre-PCI MRI (TTPCI). Cox regression was employed to evaluate relations between these risk factors and OS. Two-sided P value <0.05 was considered statistical significant. Result: 25 out of 119 (21%) LS-SCLC patients developed pre-PCI BMs, TTPCI (2.83 to 13.03 months) was revealed as an independent risk factor for pre-PCI BM (risk ratio: 1.653, 95% CI: 1.312 e 2.084, P < 0.001, Table 1 ). Patients with pre-PCI BM have significantly shorter OS (hazard ratio: 1.653, 95% CI: 1.312 e 2.084, P < 0.001, Table 1 ). Conclusion: A considerable portion of LS-SCLC patients developed BM after definitive chemoradiotherapy and immediately before PCI. We recommend mandatory CMRI before PCI in these patients. Earlier scheduled PCI may reduce BM rate in selected LS-SCLC patients, further studies are warranted to determine the optimal PCI timing for LS-SCLC patients. Keywords: small cell lung cancer, Brain metastasis, prophylactic cranial irradiation
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